Market Herald logo

Subscribe

Be the first with the news that moves the market
  • Clinical-stage cell therapy company Chimeric Therapeutics (CHM) enters a $30 million equity placement agreement with L1 Capital
  • The placement consists of the issue of an initial $500,000 worth of ordinary shares and 15 million unlisted options exercisable at 25.5 cents and expiring on March 31, 2024
  • The remaining funds will be issued under further share placements over a two-year period, but each one is subject to CHM having the capacity to issue the relevant shares
  • The funds will strengthen Chimeric’s balance sheet as the company moves forward with four phase one clinical trials
  • Chimeric is up 9.52 per cent on the market with shares trading at 11.5 cents at 11:39 am AEST

Clinical-stage cell therapy company Chimeric Therapeutics (CHM) has entered a $30 million equity placement agreement with L1 Capital.

The placement consists of the issue of an initial $500,000 worth of ordinary shares issued at 10 cents each and 15 million unlisted options exercisable at 25.5 cents and expiring on March 31, 2024.

The remaining funds will be issued under further share placements over a two-year period.

Each placement is subject to, and conditional upon, Chimeric having the available capacity to issue the relevant shares or shareholder approval.

The placement agreement allows Chimeric to maintain flexibility and enables it to undertake future capital raisings outside of the placement agreement.

The funds will strengthen Chimeric’s balance sheet as the company moves forward with four phase one clinical trials.

“L1’s commitment is testament to the quality of the company’s clinical assets, having completed significant due diligence via their specialist medical consultant based in Israel prior to executing the placement agreement,” Executive Chairman Paul Hooper said.

“With our strong existing cash reserves following the completion of the recent entitlement
offer and the flexibility this placement agreement provides, we are in a very solid position to exercise our clinical development plan with even greater confidence.”

Chimeric was up 9.52 per cent on the market with shares trading at 11.5 cents at 11:39 am AEST.

CHM by the numbers
More From The Market Herald
The Market Herald Video

" Inca Minerals (ASX:ICG) announces Adam Taylor as Chairman, restructures board

Inca Minerals (ASX:ICG) yesterday announced a restructure to its board, with Adam Taylor appointed as Chairman.

" Anson Resources (ASX:ASN) expedites resource upgrade at Paradox, US

Anson Resource (ASX:ASN) announces plans to expedite its JORC Resource upgrade at the Paradox lithium project…
The Market Herald Video

" CI Resources (ASX:CII) buys 60pc interest in Singapore fertiliser trader for $4.4m

Phosphate specialist CI Resources (ASX:CII) has officially completed its $4.4 million purchase of a 60 per…
The Market Herald Video

" Paradigm Biopharmaceuticals (ASX:PAR) activates first UK site for phase three clinical trial

Paradigm Biopharmaceuticals (ASX:PAR) has activated its first trial site in the United Kingdom for a third-phase…